The molecular pathogenesis of the philadelphia-positive leukemias: Implications for diagnosis and therapy

No abstract is available for this paper.

• Publication year

  1993

• Venue

  Cancer treatment and research

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/978-1-4615-3086-2_14
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Mutation of a phenylalanine conserved in SH3-containing tyrosine kinases activates the transforming ability of c-Abl.

  1993cited by this paper
• Point mutations in the abl SH2 domain coordinately impair phosphotyrosine binding in vitro and transforming activity in vivo

  1992cited by this paper
• Nonmyristoylated Abl proteins transform a factor-dependent hematopoietic cell line

  1992cited by this paper
• Tyrphostins inhibit PDGF-induced DNA synthesis and associated early events in smooth muscle cells.

  1991cited by this paper
• The noncatalytic src homology region 2 segment of abl tyrosine kinase binds to tyrosine-phosphorylated cellular proteins with high affinity.

  1991cited by this paper
• Interferon-alpha overrides the deficient adhesion of chronic myeloid leukemia primitive progenitor cells to bone marrow stromal cells.

  1991cited by this paper
• The use of the polymerase chain reaction for the detection of minimal residual malignant disease [editorial]

  1991cited by this paper
• Oncogenes and signal transduction.

  1991cited by this paper
• Detection of residual leukemia after bone marrow transplant for chronic myeloid leukemia: role of polymerase chain reaction in predicting relapse.

  1991cited by this paper
• BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner.

  1991cited by this paper
• Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase.

  1991cited by this paper
• Use of erbstatin as protein-tyrosine kinase inhibitor.

  1991cited by this paper
• The BCR gene encodes a novel serine/threonine kinase activity within a single exon.

  1991cited by this paper
• Clinical value of PCR in diagnosis and follow-up of leukaemia and lymphoma: report of the third Workshop of the Molecular Biology/BMT study group.

  1991cited by this paper
• A novel putative tyrosine kinase receptor with oncogenic potential.

  1991cited by this paper
• Use and specificity of genistein as inhibitor of protein-tyrosine kinases.

  1991cited by this paper
• Persistence of bcr-able gene expression following bone marrow transplantation for chronic myelogenous leukemia in chronic phase.

  1991cited by this paper
• Deficiency of a phosphatidylinositol-anchored cell adhesion molecule influences haemopoietic progenitor binding to marrow stroma in chronic myeloid leukaemia.

  1991cited by this paper
• The effects of interferon‐α on the proliferation of CML progenitor cells in vitro are not related to the precise position of the M‐BCR breakpoint

  1991cited by this paper
• Inhibition of protein-tyrosine kinases by tyrphostins.

  1991cited by this paper
• The human t(1;19) translocation in pre-B ALL produces multiple nuclear E2A-Pbx1 fusion proteins with differing transforming potentials.

  1991cited by this paper
• Interferon alpha in the therapy of CML

  1991cited by this paper
• Clonality in myeloproliferative disorders: analysis by means of the polymerase chain reaction.

  1991cited by this paper
• BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias

  1991cited by this paper
• Minimal residual disease in patients with chronic myelogenous leukemia undergoing long-term treatment with recombinant interferon alpha-2b alone or in combination with interferon gamma.

  1991cited by this paper
• axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase

  1991cited by this paper
• Tyrphostins. 2. Heterocyclic and alpha-substituted benzylidenemalononitrile tyrphostins as potent inhibitors of EGF receptor and ErbB2/neu tyrosine kinases.

  1991cited by this paper
• Alteration in bone marrow adherent layer growth factor expression: a novel mechanism of chronic myelogenous leukemia progression.

  1991cited by this paper
• Blast crisis in a murine model of chronic myelogenous leukemia.

  1991cited by this paper
• Sulfonylbenzoyl-nitrostyrenes: potential bisubstrate type inhibitors of the EGF-receptor tyrosine protein kinase.

  1991cited by this paper
• p53 in chronic myelogenous leukemia in acute phase.

  1991cited by this paper
• Evidence for regulation of the human ABL tyrosine kinase by a cellular inhibitor.

  1991cited by this paper
• Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients.

  1991cited by this paper
• Activation of tyrosinase kinase and microfilament-binding functions of c-abl by bcr sequences in bcr/abl fusion proteins

  1991cited by this paper
• Interferon-alpha alters the distribution of CFU-GM between the adherent and nonadherent compartments in long-term cultures of chronic myeloid leukemia marrow.

  1991cited by this paper
• Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides.

  1991cited by this paper
• Intensive combination chemotherapy and autologous bone marrow transplantation leads to the reappearance of philadelphia chromosome‐negative cells in chronic myelogenous leukemia

  1991cited by this paper
• Differences in oncogenic potency but not target cell specificity distinguish the two forms of the BCR/ABL oncogene.

  1991cited by this paper
• The inhibition of EGF-dependent proliferation of keratinocytes by tyrphostin tyrosine kinase blockers

  1991cited by this paper
• The role of alternative splicing patterns of BCR/ABL transcripts in the generation of the blast crisis of chronic myeloid leukaemia

  1990cited by this paper
• An E mu‐v‐abl transgene elicits plasmacytomas in concert with an activated myc gene.

  1990cited by this paper
• Analysis of cytokine mRNA and DNA: detection and quantitation by competitive polymerase chain reaction.

  1990cited by this paper
• Detection of minimal residual disease in chronic myeloid leukemia patients after bone marrow transplantation by polymerase chain reaction.

  1990cited by this paper
• Detection of breakpoint cluster region- negative and nonclonal hematopoiesis in vitro and in vivo after transplantation of cells selected in cultures of chronic myeloid leukemia marrow

  1990cited by this paper
• Rearrangement and expression of p53 in the chronic phase and blast crisis of chronic myelogenous leukemia.

  1990cited by this paper
• Src homology region 2 domains direct protein-protein interactions in signal transduction.

  1990cited by this paper
• Alpha interferon therapy for haematological malignancies: correlation between in vivo induction of the 2′,5′ oligoadenylate system and clinical response

  1990cited by this paper
• Clonal lymphoid progenitor cell lines expressing the BCR/ABL oncogene retain full differentiative function.

  1990cited by this paper
• A genetic model for colorectal tumorigenesis.

  1990cited by this paper
• Chronic myeloid leukemia may be associated with several bcr-abl transcripts including the acute lymphoid leukemia-type 7 kb transcript.

  1990cited by this paper
• Thiazolidine-diones. Biochemical and biological activity of a novel class of tyrosine protein kinase inhibitors.

  1990cited by this paper
• Expression of bcr-abl fusion transcripts following bone marrow transplantation for Philadelphia chromosome-positive leukemia.

  1990cited by this paper
• Molecular relapse in chronic myelogenous leukemia patients after bone marrow transplantation detected by polymerase chain reaction.

  1990cited by this paper
• Acute leukaemia in bcr/abl transgenic mice

  1990cited by this paper
• Interferon in the treatment of myeloproliferative diseases.

  1990cited by this paper
• Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome.

  1990cited by this paper
• Update on therapeutic options for chronic myelogenous leukemia.

  1990cited by this paper
• Activation of murine c-abl protooncogene: effect of a point mutation on oncogenic activation.

  1990cited by this paper
• bcr‐abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice.

  1990cited by this paper
• Philadelphia chromosome-negative chronic myelogenous leukemia without breakpoint cluster region rearrangement: a chronic myeloid leukemia with a distinct clinical course.

  1990cited by this paper
• Analysis of interferon-inducible genes in cells of chronic myeloid leukemia patients responsive or resistant to an interferon-alpha treatment.

  1990cited by this paper
• Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.

  1990cited by this paper
• ABL proteins in Philadelphia‐positive acute leukaemias and chronic myelogenous leukaemia blast crises

  1990cited by this paper
• Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL.

  1990cited by this paper
• Mechanism of action of α interferon in chronic granulocytic leukaemia: evidence for preferential inhibition of late progenitors

  1989cited by this paper
• Successful autografting in chronic myeloid leukaemia after maintenance of marrow in culture.

  1989cited by this paper
• A bcr-v-abl oncogene induces lymphomas in transgenic mice

  1989cited by this paper
• Detection of Philadelphia chromosome-positive cells by the polymerase chain reaction following bone marrow transplant for chronic myelogenous leukemia

  1989cited by this paper
• Tyrphostins inhibit epidermal growth factor (EGF)-receptor tyrosine kinase activity in living cells and EGF-stimulated cell proliferation.

  1989cited by this paper
• Inhibitory effects of the tyrosine kinase inhibitor genistein on mammalian DNA topoisomerase II.

  1989cited by this paper
• Comparative biochemical and cytogenetic studies of childhood acute lymphoblastic leukemia with the Philadelphia chromosome and other 22q 11 variants

  1989cited by this paper
• Molecular analysis of Philadelphia positive essential thrombocythemia.

  1989cited by this paper
• Linker insertion-deletion mutagenesis of the v-src gene: isolation of host- and temperature-dependent mutants

  1989cited by this paper
• The BCR-ABL oncogene transforms Rat-1 cells and cooperates with v-myc

  1989cited by this paper
• Tyrphostins I: synthesis and biological activity of protein tyrosine kinase inhibitors.

  1989cited by this paper
• Deletion of an N‐terminal regulatory domain of the c‐abl tyrosine kinase activates its oncogenic potential.

  1989cited by this paper
• Molecular pathogenesis of Ph-positive leukemias.

  1989cited by this paper
• Detection of residual bcr/abl translocation by polymerase chain reaction in chronic myeloid leukaemia patients after bone-marrow transplantation.

  1989cited by this paper
• N‐terminal mutations activate the leukemogenic potential of the myristoylated form of c‐abl.

  1989cited by this paper
• Induction of erythroid differentiation of K562 human leukemic cells by herbimycin A, an inhibitor of tyrosine kinase activity.

  1989cited by this paper
• Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation

  1989cited by this paper
• Detection of two alternative bcr/abl mRNA junctions and minimal residual disease in Philadelphia chromosome positive chronic myelogenous leukemia by polymerase chain reaction.

  1989cited by this paper
• Bone marrow progenitor cells induce a regulatory autologous proliferative T lymphocyte response.

  1989cited by this paper
• The common src homology region 2 domain of cytoplasmic signaling proteins is a positive effector of v-fps tyrosine kinase function

  1989cited by this paper
• Adhesive defects in chronic myeloid leukemia.

  1989cited by this paper
• Myeloproliferative disorders: usefulness of X-linked probes in diagnosis.

  1989cited by this paper
• Nucleotide sequence analysis of human abl and bcr-abl cDNAs.

  1989cited by this paper
• Six-year follow-up of the clinical significance of karyotype in acute lymphoblastic leukemia.

  1989cited by this paper
• The application of X‐chromosome gene probes to the diagnosis of myeloproliferative disease

  1989cited by this paper
• Alternative forms of the BCR-ABL oncogene have quantitatively different potencies for stimulation of immature lymphoid cells

  1989cited by this paper
• Alterations in the p53 gene and the clonal evolution of the blast crisis of chronic myelocytic leukemia.

  1989cited by this paper
• Does the site of the breakpoint on chromosome 22 influence the duration of the chronic phase in chronic myeloid leukemia?

  1989cited by this paper
• Polymerase chain reaction for detection of residual leukaemia.

  1989cited by this paper
• The bcr gene is joined to c-abl in Ph1 chromosome negative chronic myelogenous leukemia.

  1988cited by this paper
• Molecular heterogeneity of adult Philadelphia chromosome-positive acute lymphoblastic leukemia.

  1988cited by this paper
• Fusion of the bcr and the c-abl genes in Ph'-positive acute lymphocytic leukemia with no rearrangement in the breakpoint cluster region.

  1988cited by this paper
• Biology of chronic myelogenous leukemia: is discordant maturation the primary defect?

  1988cited by this paper
• Expression of a distinctive BCR-ABL oncogene in Ph1-positive acute lymphocytic leukemia (ALL).

  1988cited by this paper
• Lack of breakpoint cluster region rearrangement in marrow fibroblasts of patients with Philadelphia chromosome-positive chronic myelogenous leukemia.

  1988cited by this paper
• Staging and prognosis in chronic myelogenous leukemia.

  1988cited by this paper

• Modeling Human Philadelphia Chromosome-Positive Leukemia in Mice

  2008cites this paper
• Mouse Models of Human Blood Cancers

  2008cites this paper
• BCR/ABL-mediated downregulation of genes implicated in cell adhesion and motility leads to impaired migration toward CCR7 ligands CCL19 and CCL21 in primary BCR/ABL-positive cells

  2005cites this paper
• Chronic myelogenous leukemia as a paradigm of early cancer and possible curative strategies

  2003cites this paper
• The src homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase.

  2001cites this paper
• The Grb2 binding site is required for the induction of chronic myeloid leukemia-like disease in mice by the Bcr/Abl tyrosine kinase.

  2000cites this paper
• Reduced oncogenicity of p190 Bcr/Abl F-actin-binding domain mutants.

  2000cites this paper
• Clinical significance of reverse BCR/ABL gene rearrangement in Ph-negative chronic myelogenous leukemia.

  2000cites this paper
• Oncogenes and tumor suppressor genes: therapeutic implications.

  1997cites this paper
• BCR/ABL‐negative chronic myeloid leukemia with ETV6/ABL fusion

  1997cites this paper
• Detection of BCR-ABL transcripts from the Philadelphia translocation by hybridization in microtiter wells and time-resolved immunofluorometry.

  1995cites this paper
• BCR/ABL P210 and P190 cause distinct leukemia in transgenic mice.

  1995cites this paper
• Increased neutrophil respiratory burst in bcr-null mutants.

  1995cites this paper
• Tyrosine phosphorylation of CRKL in Philadelphia+ leukemia.

  1994cites this paper